In NSCLC patients with canonical EGFR mutations, osimertinib is a third-generation TKI developed to overcome resistance to the EGFR T790M mutation [69], shown to exhibit penetrance of the blood–brain barrier in non-human primate studies [70]. Here, EGFR is linked to non-small cell lung carcinoma.